Last reviewed · How we verify
VOSORITIDE
At a glance
| Generic name | VOSORITIDE |
|---|---|
| Modality | Recombinant protein |
| Phase | FDA-approved |
| First approval | 2021 |
Approved indications
Common side effects
- Injection site reactions
- Injection site erythema
- Injection site swelling
- Rash
- Vomiting
- Injection site urticaria
- Arthralgia
- Decreased blood pressure
- Gastroenteritis
- Increase in alkaline phosphatase
- Injection site pain
- Injection site bruising
Serious adverse events
- Symptomatic decreased blood pressure with vomiting and/or dizziness
Key clinical trials
- Vosoritide for Selected Genetic Causes of Short Stature (PHASE2)
- A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months (PHASE2)
- A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature (PHASE2)
- A Clinical Trial to Evaluate Safety of Vosoritide in At-risk Infants With Achondroplasia (PHASE2)
- An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia (PHASE3)
- An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia (PHASE2)
- A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH) (PHASE2)
- Safety and Efficacy of Voxzogo for Growth Deficits in MPS IVA and VI (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VOSORITIDE CI brief — competitive landscape report
- VOSORITIDE updates RSS · CI watch RSS